Background and Purpose—Most stroke patients do not present for medical treatment until
several hours after onset of brain ischemia. Consequently, neuroprotective strategies are …

Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …

The brain inflammatory response induced by stroke contributes to cell death and impairs
neurogenesis. Poly (ADP-ribose) polymerase-1 (PARP-1) is a coactivator of the transcription …

In patients with stroke and neurodegenerative diseases, overactivation of poly (ADP-ribose)
polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis …

Background and purpose: Activation of poly (ADP‐ribose) polymerase (PARP) is deleterious
during cerebral ischemia. We assessed the influence of PARP activation induced by …

Focal cerebral ischemia activates the nuclear protein poly (ADP-ribose) polymerase (PARP)
by single DNA strand breaks which leads to energy depletion and cell necrosis. Deletion or …

Overactivation of poly (ADP-ribose) polymerase-1 (PARP-1) in response to DNA damage is
considered to play a crucial role in the development of post-ischemic neuronal injury, such …

Recombinant tissue‐type plasminogen activator (rt‐PA) is presently the only
pharmacological treatment approved for thrombolysis in patients suffering from ischemic …

N-[3-(4-Oxo-3, 4-dihydro-phthalazin-1-yl) phenyl]-4-(morpholin-4-yl) butanamide
methanesulfonate monohydrate (ONO-1924H) is a novel inhibitor of poly ADP-ribose …

Recombinant tissue plasminogen activator (rt-PA) is the only pharmacological treatment
approved for thrombolysis in patients suffering from ischemic stroke, but its administration …